The Union health ministry said on Monday that the number of blood clot cases in people who received AstraZeneca's Covid-19 vaccine (called Covishield) in India was "minuscule". Covishield - one of three shots granted emergency approval in India - is the most widely used in the country and is manufactured by Pune-based Serum Institute (SII). Also Read: Details of thromboembolic events after Covid-19 vaccinationThromboembolic events refer to the formation of a clot in a blood vessel that might also break loose and be carried by the bloodstream to plug another vessel. The ministry separately released advisories to healthcare workers and vaccine beneficiaries to encourage people to be aware of suspected thromboembolic symptoms. These symptoms, the ministry said, occur within 20 days of taking a shot (particularly Covishield) and asked the beneficiaries to report to the health facility where vaccine was administered.

Source: Hindustan Times May 18, 2021 02:53 UTC